Utilized for major depressive disorder to manage mood balance and support improved sleep quality.
Mechanism of Action
Mirtazapine acts as an antagonist at central presynaptic alpha-2 adrenergic receptors, which increases both noradrenergic and serotonergic neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors and has high affinity for H1 histamine receptors.
Route of Administration
Oral
Onset Time
1–4 weeks
Duration
20–40 hours (half-life)
Contraindications
Concurrent use of MAO inhibitors, Hypersensitivity to mirtazapine
Severe Adverse Events
Agranulocytosis, Serotonin syndrome, Suicidal ideation — requires immediate medical attention
Common Side Effects
Somnolence, Increased appetite, Weight gain
Uncommon Side Effects
Dry mouth, Constipation, Dizziness
Drug Interactions
Alcohol, MAO Inhibitors, Warfarin, Lorazepam, Tramadol
Pregnancy Safety Warnings
FDA Category C: Use only if clearly needed. Breastfeeding: Excreted in milk; monitor infant.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Information related to Mirtazapine is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
